| Cat. No. |
Product Name |
Information |
| PC-73081 |
Amphihevir
|
Amphihevir is a potent, selective HCV NS4B inhibitor with EC50 of 0.34 and 1.97 nM against the GT1a (H77) and GT1b replicon in luciferase assays. |
| PC-72892 |
Dichlorcyclizine
|
Dichlorcyclizine (DCCZ) is a potent, small molecule HCV fusion inhibitor, also inhibits SARS-CoV and SARS-CoV-2 S-mediated infection with EC50 of 9.92 and 4.53 uM, respectively. |
| PC-72891 |
Fluoxazolevir
|
Fluoxazolevir (NCGC00351982) is a potent, small molecule entry inhibitor of HCV with EC50 of 18.8 nM. |
| PC-72626 |
AT-527
|
AT-527 (AT527, Bemnifosbuvir hemisulfate, RG-6422) is a novel phosphoramidate prodrug of AT-511 that has potent in vitro activity against HCV (EC50=5-28 nM), also inhibits replication of SARS-CoV-2 with EC90 of 0.47 uM. |
| PC-63383 |
GSK-2878175
|
GSK-2878175 (GSK8175, GSK-175, GSK-175A) is a potent, pan-genotypic, second generation HCV NS5B palm polymerase inhibitor with EC50 of 0.4-9.7 nM. |
| PC-61440 |
Voxilaprevir
|
Voxilaprevir (GS-9857) is a potent HCV NS3/4A protease inhibitor that is used in combination with sofosbuvir and velpatasvir for treatment of HCV infection.. |
| PC-60952 |
Deleobuvir
|
Deleobuvir (BI-207127, BI207127) is a potent, selective HCV NS5B polymerase inhibitor with IC50 of 50 nM against GT-1 HCV polymerase activity. |
